Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7886739 | 0.92 | CYP2D6 (0.50) | CYP2D6KDM4ETSHRTDP1 | |
| SCHEMBL14417920 | 0.85 | CYP2D6 (0.39) | CYP2D6TSHRTDP1 | |
| SCHEMBL13913307 | 0.83 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL27422934 | 0.82 | CYP2D6 (0.37) | CYP2D6TSHRTDP1 | |
| SCHEMBL24040088 | 0.82 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL11982156 | 0.82 | CYP2D6 (0.41) | CYP2D6KDM4E | |
| SCHEMBL13066194 | 0.80 | TSHR (0.39) | CYP2D6TSHRTDP1 | |
| SCHEMBL13632467 | 0.78 | — | — | |
| SCHEMBL8858904 | 0.78 | — | — | |
| SCHEMBL12345554 | 0.77 | CYP2D6 (0.53) | CYP2D6KDM4ETSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPOSEUTICALS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPC, FUT6, UGCG | CYP2D6 408/4885KDM4E 2535/4885TSHR 3962/4885 |
| US-20080200476-A1 | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | KCNH1, CACNA1B, CACNA1C | CYP2D6 1708/4885KDM4E 3281/4885TSHR 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.